Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability

Stephen Sawada, Saumyadip Dasgupta, James Nguyen, Kathleen A. Lane, Irmina Gradus-Pizlo, Jothiharan Mahenthiran, Harvey Feigenbaum

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Short-term survival in patients with viability and ischemic left ventricular dysfunction appears improved by revascularization, but no randomized studies have shown a long-term benefit of revascularization in patients with a wide range of viability. Propensity analysis was used as a substitute for randomization in a study comparing the survival of revascularized and medically treated patients with ischemic dysfunction. Dobutamine echocardiography was performed in 274 patients with ischemic left ventricular dysfunction (mean ejection fraction 32%), with 32% having viability in ≥25% of the myocardium. Clinical, angiographic, and echocardiographic characteristics were comparable between treatment groups except for multivessel disease, hyperlipidemia, and the percentage of nonviable myocardium. A propensity score, reflecting the probability of receiving revascularization, was derived for each patient from baseline variables. After stratification by propensity scores, there were no differences between groups. Patients were followed for cardiac death. Revascularization was performed in 130 patients, and 144 were medically treated. There were 114 cardiac deaths (42%) over 4.5 years of follow-up. After propensity score adjustment, survival was better with revascularization (mean survival 5.9 vs 3.3 years, hazard ratio 0.42, 95% confidence interval 027 to 0.65, p <0.0001). Medical and device therapy during follow-up was similar between treatment groups, except that β-blocker use was more common in revascularized patients. After adjustment for β-blocker use and propensity score, survival remained better in revascularized patients (hazard ratio 0.47, 95% confidence interval 0.30 to 0.72, p = 0.0006). In conclusion, revascularization improves long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalThe American Journal of Cardiology
Volume106
Issue number2
DOIs
StatePublished - Jul 15 2010

Fingerprint

Left Ventricular Dysfunction
Survival
Propensity Score
Myocardium
Confidence Intervals
Dobutamine
Random Allocation
Hyperlipidemias
Echocardiography
Therapeutics
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability. / Sawada, Stephen; Dasgupta, Saumyadip; Nguyen, James; Lane, Kathleen A.; Gradus-Pizlo, Irmina; Mahenthiran, Jothiharan; Feigenbaum, Harvey.

In: The American Journal of Cardiology, Vol. 106, No. 2, 15.07.2010, p. 187-192.

Research output: Contribution to journalArticle

Sawada, Stephen ; Dasgupta, Saumyadip ; Nguyen, James ; Lane, Kathleen A. ; Gradus-Pizlo, Irmina ; Mahenthiran, Jothiharan ; Feigenbaum, Harvey. / Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability. In: The American Journal of Cardiology. 2010 ; Vol. 106, No. 2. pp. 187-192.
@article{cf9bc42aec0e4f4f9cb4687a073196b0,
title = "Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability",
abstract = "Short-term survival in patients with viability and ischemic left ventricular dysfunction appears improved by revascularization, but no randomized studies have shown a long-term benefit of revascularization in patients with a wide range of viability. Propensity analysis was used as a substitute for randomization in a study comparing the survival of revascularized and medically treated patients with ischemic dysfunction. Dobutamine echocardiography was performed in 274 patients with ischemic left ventricular dysfunction (mean ejection fraction 32{\%}), with 32{\%} having viability in ≥25{\%} of the myocardium. Clinical, angiographic, and echocardiographic characteristics were comparable between treatment groups except for multivessel disease, hyperlipidemia, and the percentage of nonviable myocardium. A propensity score, reflecting the probability of receiving revascularization, was derived for each patient from baseline variables. After stratification by propensity scores, there were no differences between groups. Patients were followed for cardiac death. Revascularization was performed in 130 patients, and 144 were medically treated. There were 114 cardiac deaths (42{\%}) over 4.5 years of follow-up. After propensity score adjustment, survival was better with revascularization (mean survival 5.9 vs 3.3 years, hazard ratio 0.42, 95{\%} confidence interval 027 to 0.65, p <0.0001). Medical and device therapy during follow-up was similar between treatment groups, except that β-blocker use was more common in revascularized patients. After adjustment for β-blocker use and propensity score, survival remained better in revascularized patients (hazard ratio 0.47, 95{\%} confidence interval 0.30 to 0.72, p = 0.0006). In conclusion, revascularization improves long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability.",
author = "Stephen Sawada and Saumyadip Dasgupta and James Nguyen and Lane, {Kathleen A.} and Irmina Gradus-Pizlo and Jothiharan Mahenthiran and Harvey Feigenbaum",
year = "2010",
month = "7",
day = "15",
doi = "10.1016/j.amjcard.2010.03.014",
language = "English",
volume = "106",
pages = "187--192",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability

AU - Sawada, Stephen

AU - Dasgupta, Saumyadip

AU - Nguyen, James

AU - Lane, Kathleen A.

AU - Gradus-Pizlo, Irmina

AU - Mahenthiran, Jothiharan

AU - Feigenbaum, Harvey

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Short-term survival in patients with viability and ischemic left ventricular dysfunction appears improved by revascularization, but no randomized studies have shown a long-term benefit of revascularization in patients with a wide range of viability. Propensity analysis was used as a substitute for randomization in a study comparing the survival of revascularized and medically treated patients with ischemic dysfunction. Dobutamine echocardiography was performed in 274 patients with ischemic left ventricular dysfunction (mean ejection fraction 32%), with 32% having viability in ≥25% of the myocardium. Clinical, angiographic, and echocardiographic characteristics were comparable between treatment groups except for multivessel disease, hyperlipidemia, and the percentage of nonviable myocardium. A propensity score, reflecting the probability of receiving revascularization, was derived for each patient from baseline variables. After stratification by propensity scores, there were no differences between groups. Patients were followed for cardiac death. Revascularization was performed in 130 patients, and 144 were medically treated. There were 114 cardiac deaths (42%) over 4.5 years of follow-up. After propensity score adjustment, survival was better with revascularization (mean survival 5.9 vs 3.3 years, hazard ratio 0.42, 95% confidence interval 027 to 0.65, p <0.0001). Medical and device therapy during follow-up was similar between treatment groups, except that β-blocker use was more common in revascularized patients. After adjustment for β-blocker use and propensity score, survival remained better in revascularized patients (hazard ratio 0.47, 95% confidence interval 0.30 to 0.72, p = 0.0006). In conclusion, revascularization improves long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability.

AB - Short-term survival in patients with viability and ischemic left ventricular dysfunction appears improved by revascularization, but no randomized studies have shown a long-term benefit of revascularization in patients with a wide range of viability. Propensity analysis was used as a substitute for randomization in a study comparing the survival of revascularized and medically treated patients with ischemic dysfunction. Dobutamine echocardiography was performed in 274 patients with ischemic left ventricular dysfunction (mean ejection fraction 32%), with 32% having viability in ≥25% of the myocardium. Clinical, angiographic, and echocardiographic characteristics were comparable between treatment groups except for multivessel disease, hyperlipidemia, and the percentage of nonviable myocardium. A propensity score, reflecting the probability of receiving revascularization, was derived for each patient from baseline variables. After stratification by propensity scores, there were no differences between groups. Patients were followed for cardiac death. Revascularization was performed in 130 patients, and 144 were medically treated. There were 114 cardiac deaths (42%) over 4.5 years of follow-up. After propensity score adjustment, survival was better with revascularization (mean survival 5.9 vs 3.3 years, hazard ratio 0.42, 95% confidence interval 027 to 0.65, p <0.0001). Medical and device therapy during follow-up was similar between treatment groups, except that β-blocker use was more common in revascularized patients. After adjustment for β-blocker use and propensity score, survival remained better in revascularized patients (hazard ratio 0.47, 95% confidence interval 0.30 to 0.72, p = 0.0006). In conclusion, revascularization improves long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability.

UR - http://www.scopus.com/inward/record.url?scp=77955708810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955708810&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2010.03.014

DO - 10.1016/j.amjcard.2010.03.014

M3 - Article

C2 - 20599001

AN - SCOPUS:77955708810

VL - 106

SP - 187

EP - 192

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 2

ER -